Physicians recognize the importance of ventricular assist devices (VADs) every time a congestive heart failure (CHF) patient awaiting transplantation gets a therapeutic bridge. But VADs are playing an increasingly critical role not just in improving patient outcomes but also in cutting overall healthcare costs.
With the recent introduction of new VAD models and upgrades in the U.S., in addition to new devices entering final clinical trials this year, these technological innovations promise to further bridge the gaps in both patient care and healthy healthcare spend.